Status:
TERMINATED
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
Lead Sponsor:
National Atomic Research Institute, Taiwan
Conditions:
Tumors
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
This is a study to determine the maximum tolerance dose (MTD) and to evaluate the safety of 188Re-BMEDA-liposome in patient with primary solid tumor in advanced or metastatic stage.
Detailed Description
Rhenium-188 is an ideal radionuclide for therapeutic use due to its maximum beta emission of 2.12MeV, short physical half-life of 16.9 hours, and its 155-keV gamma emission for imaging purposes. 188Re...
Eligibility Criteria
Inclusion
- Patient with histologically confirmed diagnosis of primary solid tumor, and with pathologically or radiologically documented metastases
- Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)
- Patient with metastatic cancer that are refractory to current standard/available therapies
Exclusion
- brain metastases
- serious concurrent infection or nonmalignant illness that is uncontrolled
- uncontrolled intercurrent illness
- Immunocompromised
- significant traumatic injury within 3 weeks before Day 0
- History of hypersensitivity to any component of study drug
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT02271516
Start Date
October 1 2014
End Date
December 1 2014
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital (Taiwain)
Taipei, Taiwan, 11217